drugset / Trial / NCT07546942

Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.

NCT07546942

Phase 1/2 Enrolling by invitation 50 enrolled Black Tie Medical, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Autism spectrum disorder (ASD) is a neurodevelopmental condition with core deficits in social communication and behavior, often accompanied by gastrointestinal (GI) and metabolic dysfunction. Emerging evidence supports the role of neuroinflammation (including autoimmune components), gut-brain axis disruption, and metabolic dysregulation in ASD pathophysiology. Multimodal interventions targeting these pathways-using autologous cSVF, cryopreserved MSCs, FMT, and dietary modulation-intent is that these multimodal interventions may offer synergistic benefits for adolescents and adults with ASD.

Timeline

Start
2026-04-30
Primary completion
2030-06-01
Completion
2030-08-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cellular Stromal Vascular Fraction Cell therapy 1e+07 cells Intravenous
Subject Cellular Stromal Vascular Fraction Cell therapy 5e+07 cells Intravenous
Subject mesenchymal stem cells Cell therapy 1e+06 cells Intravenous
Subject mesenchymal stem cells Cell therapy 3e+07 cells Intravenous

Indications